Glenmark launches drug for malaria treatment in UK
The European unit of the company has launched its first product in Britain.
New Delhi, February 7, 2013: Glenmark Pharmaceuticals Ltd has announced that the European unit of the company has launched the generic version of GlaxoSmithKline's Malarone malaria treatment medicine. It is worth mentioning here that it is the first product from the company in Britain.
The company said in a statement that it has launched the drug after the revocation of Glaxo's patent on Malarone by the High Court in Britain and the medicine registered sales worth US$ 28 million for the year ended September 2012.